Headlands Technologies’s Tarsus Pharmaceuticals TARS Stock Holding History

Headlands Technologies’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,322	Closed	-$303K	–	980
2026 Q1	$303K	Buy	+4,322	New	+$302K	0.03%	494

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Headlands Technologies's TARS Position: Q2 2026 in Review

Headlands Technologies sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 4,322 shares — an estimated $303K sold.

Headlands Technologies first reported a position in TARS in Q1 2026 and held it in 1 quarter. The position peaked at $303K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Headlands Technologies reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Headlands Technologies sold 4,322 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $303K.
Headlands Technologies first reported a position in Tarsus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Headlands Technologies's Tarsus Pharmaceuticals position peaked at $303K in Q1 2026.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.